

CERTIFICATE OF ANALYSIS

Product Name:	Olmesartan Medoxomil		
Batch No.	D5467-22-002		
Batch Type	Commercial	Batch Size	255.58kg
Retest Date	July, 2027	Report Date	August 23, 2022
Manufacturing Date	August 10, 2022	Reference	USP
Analytical Results			
Items	Specifications		Results
Description	White or almost white, crystalline powder		White crystalline powder
Identification	1) The infrared absorption spectrum is concordant with the spectrum obtained with Olmesartan Medoxomil RS.		Conform
	2) The retention time of the major peak in the chromatogram of the Test solution corresponds to that in the chromatogram of the Reference solution, as obtained in the Assay.		Conform
Water	≤0.5%		0.1%
Residue on ignition	≤0.1%		<0.1%
Related substances (HPLC)	Olmesartan ≤0.4%		0.05%
	Olmesartan medoxomi related compound A ≤0.10%		<LOD(LOD:0.01%)
	Olefinic impurity ≤0.3%		<LOD(LOD:0.02%)
	N-alkyl impurity ≤0.10%		<LOD(LOD:0.02%)
	Ethyl-Olmesartan Medoxomi ≤0.10%		<LOQ(LOQ:0.05%)
	Any other individual unidentified impurities ≤0.10%		0.05%
	Total unidentified impurities ≤0.3%		0.05%
	Total impurities ≤0.7%		0.10%
Assay (HPLC)	98.5%~101.5% (on anhydrous and solvent-free basis)		99.9%
Residual solvents (GC)	Ethanol ≤5000ppm		<LOD(LOD:30ppm)
	Acetic acid ≤5000ppm		<LOQ(LOQ:54ppm)
	Toluene ≤890ppm		<LOD(LOD:27ppm)
	Acetone ≤5000ppm		1160ppm
	Ethyl acetate ≤5000ppm		<LOD(LOD:30ppm)
Storage Condition	Preserved in well-closed containers		
Conclusion	Complies with USP		

Inspector: Carlifor Wu

Verifier: Jack He